Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators.

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.

PMID:
23246022
2.

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.

Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC; IES Trial Steering Committee.

Br J Cancer. 2012 Mar 13;106(6):1062-7. doi: 10.1038/bjc.2012.43. Epub 2012 Feb 21.

3.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
4.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

5.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

6.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

7.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

8.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

9.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI; TAX 324 Study Group.

Ann Oncol. 2009 May;20(5):921-7. doi: 10.1093/annonc/mdn752. Epub 2009 Jan 29.

PMID:
19179556
10.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

11.

Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey.

Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, Vallejos C, Guercovich A; Latin American and Caribbean Society of Medical Oncology.

Cancer. 2008 Oct 15;113(8 Suppl):2359-65. doi: 10.1002/cncr.23834.

12.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group.

N Engl J Med. 2007 Oct 25;357(17):1705-15.

13.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

PMID:
17307102
14.

Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.

Delfino C, Caccia G, Gonzáles LR, Mickiewicz E, Rodger J, Balbiani L, Morales DF, Comba AZ, Brosio C.

Oncology. 2004;66(1):18-23.

PMID:
15031594
15.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study.

N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461. N Engl J Med. 2006 Oct 19;355(16):1746. van de Velde, Cornelius [added].

16.

Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.

Delfino C, Caccia G, Riva Gonzáles L, Mickiewicz E, Rodger J, Balbiani L, Flores Morales D, Zori Comba A, Brosio C.

Oncology (Williston Park). 2003 Dec;17(12 Suppl 14):22-5.

17.

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.

Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Cóppola F, Van Kooten M, Rodger J, Giglio R, Balbiani L, Perazzo F, Montiel M, Chacón M, Pujol F, Mickiewicz E, Cazap E, Recondo G, Lastiri F, Simon J, Wasserman E, Schmilovich A.

Eur J Cancer. 2001 May;37(8):1006-13.

PMID:
11334726
18.

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G.

J Clin Oncol. 2000 Jun;18(11):2234-44.

PMID:
10829043
19.

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study.

Lhommé C, Vermorken JB, Mickiewicz E, Chevalier B, Alvarez A, Mendiola C, Pawinski A, Lentz MA, Pecorelli S.

Eur J Cancer. 2000 Jan;36(2):194-9.

PMID:
10741277
20.

Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.

Pazos C, Mickiewicz E, Di Notto MR, Cóppola F, Ventriglia M, Jovtis S, Balbiani L, Lewi D, Róndinón M, Témperley G, Trigo M, Bertoncín AM, Pascual M, Uranga G, Cazap E, Breier S, Grasso S, Estévez R, Triguboff E, Alvarez A, Suárez A.

Breast Cancer Res Treat. 1999 May;55(1):91-6.

PMID:
10472783

Supplemental Content

Loading ...
Support Center